
Pfizer appoints new chief scientific officer for neuroscience research
pharmafile | September 7, 2016 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |
Dr Ole Isacson has been named as the chief scientific officer at Pfizer’s neuroscience research unit.
He will continue to serve an educational role at Harvard Medical School, where he currently holds the role of professor of neurology. Additionally, Dr Isacson is a founding director of the neuroregeneration institute at McLean Hospital.
Receiving his medical bachelor and doctor of medicine degrees from the University of Lund in Sweden, Dr Isacson held a two year postdoctoral fellowship at Cambridge University before joining Harvard. Over the last two decades, his work has become renowned for his research on Parkinson’s disease and other neurodegenerative disorders.
At Pfizer, he will report to Mikael Dolsten, president of worldwide research and development.
Dr Dolsten says: “Dr Isacson’s deep expertise in neurodegenerative disorders is well-aligned with our work in Alzheimer’s and Parkinson’s disease, where we are working to advanced potential breakthrough therapies to fill the tremendous unmet need that exists for patients. In addition, his strong ties in the local academic community will be important as our Cambridge site continues to drive collaborations with leading scientific and academic institutions that can help us speed the pace of discovery.”






